NorthStrive Expands EL-22 Patent Coverage for Muscle-Wasting Treatments
Event summary
- NorthStrive Biosciences filed a new U.S. patent application (No. 19/655,160) for EL-22 formulations and dosing regimens on April 28, 2026.
- The application covers treatments for muscle-wasting conditions related to GLP-1 use, sarcopenia, muscle disuse atrophy, and neurological disorders.
- EL-22 is a myostatin-engineered probiotic designed for muscle preservation across multiple indications.
- This filing expands NorthStrive’s intellectual property portfolio around EL-22.
The big picture
NorthStrive’s expanded patent coverage for EL-22 reflects the growing recognition of muscle-wasting as a critical concern in aging populations and chronic disease management. The filing aligns with broader industry trends toward targeted therapeutics for metabolic health, particularly as GLP-1 receptor agonists gain prominence in obesity and diabetes treatment. PMGC Holdings’ strategic focus on muscle health positions NorthStrive to capitalize on this emerging therapeutic niche.
What we're watching
- Patent Strategy
- How NorthStrive’s layered IP approach will position EL-22 in competitive muscle-wasting treatment markets.
- Clinical Validation
- Whether EL-22 can demonstrate efficacy across the broad range of indications claimed in the patent application.
- Market Expansion
- The pace at which NorthStrive can translate patent filings into commercial partnerships or regulatory approvals.
Related topics